SpaceX's Lockup Cliff and the 2026 IPO Pipeline's Reality Check

The IPO market’s 2026 revival is about to meet its first real stress test. SpaceX (SPCX), which raised $75 billion in June in the largest initial public offering on record, has already surrendered nearly all its post-listing premium — closing at $115.07 on July 24, below its $135 offering price and down 47% from the June 16 peak of $211.39.^[1][2] The decline is unfolding ahead of a critical inflection: SpaceX reports its first quarterly earnings on August 4, and two days later the lockup restrictions that have kept pre-IPO shareholders from selling begin to expire.^[3]

That expiration is not a one-off. It is the leading edge of a supply wave that will determine whether the 2026 IPO recovery sustains itself or buckles under the weight of its own success. The base-rate signal is not encouraging: roughly 60% of stocks historically decline around lockup expiry, and SpaceX is entering that window already trading below its offer price.

The 2026 IPO Scoreboard

Through July 20, 203 companies have gone public on US exchanges — a 6.8% increase from the 190 IPOs recorded by the same date in 2025.^[4] Among deals with a market capitalization of at least $50 million, 86 IPOs have raised $142.4 billion in total proceeds.^[5] The Renaissance IPO Index returned 30.3% year-to-date through late June, more than triple the S&P 500’s 9.6%.^[5]

But the second quarter’s strength was disproportionately concentrated. SpaceX alone raised $75 billion — more than all of 2025’s IPOs combined — and nine other deals each raised over $1 billion.^[5] Strip out SpaceX, and the deal flow is robust but less extraordinary.

Prices as of 16:00 ET close on July 24, 2026.^[6] Returns from Renaissance Capital, confirmed against live quotes.^[5] SK hynix offer price derived from reported $26.5B raise for 177.9M ADRs.^[7]

The dispersion is striking. Scribe Therapeutics, a CRISPR gene-editing company co-founded by Jennifer Doudna, priced at the high end of its $13–$15 range and popped 44% in its first session — a signal that biotech demand remains intact for differentiated science.^[4] Meanwhile, two AI-infrastructure deals that priced the prior week both stumbled: data-center operator Csquare priced below its range and Standard Nuclear slashed its offering by more than half before plunging 41%.^[5] QumulusAI, an AI compute name, is down nearly 48% from its offer. The pattern suggests that the market is being selective: stories with proprietary technology and clear commercial paths are getting funded, while companies riding the AI-infrastructure thematic without differentiation are finding the door closing.

SK hynix and the Foreign-Listing Wave

The largest foreign IPO in US history landed on July 9, when SK hynix (SKHY) raised $26.5 billion through 177.9 million American depositary receipts on Nasdaq.^[7] The South Korean memory chipmaker — the world’s fourth-largest DRAM producer and a critical supplier of high-bandwidth memory stacked alongside Nvidia’s AI accelerators — opened at $170, a 13% first-day pop, before settling to $154.57 as of the July 24 close.^[6][7]

The listing matters beyond its size. It establishes a template for other foreign issuers seeking US market depth and dollar-denominated capital, and it arrives amid a broader selloff in semiconductor stocks that pulled SK hynix’s home-listed shares down 25% in the three weeks before the offering.^[7] The ADRs are now roughly flat to slightly above the approximate $149 offer price — respectable, but not the momentum underwriters hoped to sustain. If SK hynix drifts below its IPO price in the coming weeks, it would mark the second mega-deal of 2026 (after SpaceX) trading underwater, a data point that could cool the cross-border pipeline.

The SpaceX Lockup Cliff

SpaceX’s trajectory from record-setting debut to below-IPO-price trading is the defining story of the 2026 IPO market. The stock peaked at $211.39 on June 16 — four days after its June 12 listing — giving the company a market value above $2.1 trillion.^[2] Since then, it has been a one-directional slide: $115.07 as of the July 24 close, with short interest reported at 32% and the stock testing its all-time low near $111.^[1][2]

The lockup structure makes August the pivot point. SpaceX set August 4 as its first earnings report date, and under the terms of its IPO, most pre-IPO investors become eligible to sell two days after that release — August 6.^[3] Morningstar estimates that billions of shares will become sellable over the coming months as tranches of lockup restrictions roll off, and as the float expands, index funds will need to increase their weightings — creating a complex dynamic of forced buying and discretionary selling hitting the tape simultaneously.^[3]

The 60/40 read: there is a roughly 60% probability that the lockup expiry exerts further downward pressure on SPCX in the near term, given the stock is already below its offer price, short interest is elevated at 32%, and post-IPO momentum has fully reversed. The 40% case requires the earnings report to deliver a catalyst strong enough to absorb the incoming supply — Starship progress, Starlink economics, or revenue acceleration that shifts the narrative from “supply overhang” to “growth re-rating.”

Jersey Mike’s and the Consumer Pipeline

While SpaceX and SK hynix dominated headlines, the consumer sector is preparing its own test. Jersey Mike’s Subs filed its S-1 on July 2 and launched its roadshow on July 20, targeting a NYSE debut under the ticker JMKE on July 30.^[8] The offering comprises 43.5 million Class A shares at $21 to $25 per share, with a midpoint of $23 implying a market capitalization of approximately $7.3 billion and a maximum raise of $1.09 billion.^[8]

The deal is notable for what it is not: an AI story, a biotech platform, or a semiconductor play. It is a roughly 99% franchised sandwich chain with over 3,000 locations — the kind of “real economy” business that IPO watchers have been waiting to see test the market.^[8] If Jersey Mike’s prices within its range and trades well, it widens the IPO aperture beyond tech and biotech. If it struggles, it confirms that the 2026 new-issue market remains selective about sector and narrative.

The Liquidity Paradox: Volume Up, Depth Down

Beneath the IPO headlines, a structural shift in market plumbing is quietly reshaping how all of these new shares trade. Dark pool trading volume reached $2.1 trillion year-to-date through June 2026, with off-exchange venues accounting for 16% of US equity trades that month — up 340% from 2016 levels.^[9] At the same time, order book depth has contracted 23% since Q1 2026, meaning the visible liquidity available at the best prices is thinner even as headline trading volume surges.^[10][9]

For newly public companies, this matters in concrete ways. Thinner depth means larger orders move prices more — and for IPO stocks that typically have limited float in their early months, the combination of concentrated selling at lockup expiry and reduced market-depth cushions could amplify volatility. The Liquidnet Q2 2026 market structure outlook notes that trading has shifted back toward lit venues even as off-exchange behavior evolves, but the underlying complexity for institutional execution remains “challenging.”^[9]

The implication for the IPO pipeline is straightforward: the market can absorb new issuance at the headline level — $142 billion raised year-to-date says it can — but the quality of that absorption is degrading. More volume is routing through dark venues; less liquidity is sitting in the lit book; and the depth that newly public companies need to absorb lockup-driven supply waves is thinner than the headline numbers suggest.

What to Watch Next

1. SpaceX earnings (August 4) and lockup expiry (August 6). The first real test of whether the largest IPO in history can absorb insider supply. Watch for volume and price action in the days following August 6 — if the stock stabilizes, the overhang narrative fades; if it breaks below $111 (its all-time low), the supply pressure is winning.

2. Jersey Mike’s debut (July 30). The first major consumer-franchise IPO of 2026. A clean pricing within the $21–$25 range and stable first-week trading would broaden the market’s risk appetite beyond tech and biotech.

3. SK hynix post-IPO stabilization. SKHY at $154.57 is hovering near its approximate $149 offer price. A break below that level would put the largest foreign listing in US history underwater — a signal that could cool the cross-border pipeline.

4. Dark pool share and order book depth. If off-exchange volume continues climbing past 16% and depth keeps contracting, the execution environment for large block trades — including lockup-driven selling from SpaceX and other 2026 IPOs — will worsen, potentially widening spreads and increasing the cost of clearing supply.

5. The August IPO calendar. Renaissance Capital’s calendar lists multiple deals for the coming weeks,^[11] and if the SpaceX lockup passes without systemic disruption, the pipeline is likely to accelerate into September. The base case is that 2026 finishes with 120–140 priced deals of $50M+ — a meaningful recovery from 2025, but one whose trajectory depends heavily on whether the largest deal in history becomes a cautionary tale or a footnote.

Sources

1. Quote: SPCXFN2 market data
2. Space Exploration Technologies Corp - Class A (SPCX) | Currently at $115.07 (-2.68%) | Ju…exa.ai
3. SpaceX sets earnings date, triggering first big share unlockcnbc.com
4. CXMT poised to become biggest China-listed firm on trading debut amid memory chip investm…businesstimes.com.sg
5. IPO News - US IPO Weekly Winners & Losersrenaissancecapital.com
6. Quote: SKHYFN2 market data
7. SK Hynix rises 13% in Nasdaq debut. Chairman says 'demand is enormous'cnbc.com
8. S-1sec.gov
9. Let There Be Light: US Edition | Market Structure Reportsrblt.com
10. Top Themes Heading into 2026: Market Structure, Liquidity and ...flextrade.com
11. IPO Event Calendar | Stock Market Event Calendar | IPO Calendara2zipo.com